Phaseline

Targets › HRAS

HRAS (GTPase HRas): drug programs, companies and trials

6 programs from 5 companies in 8 trials: 7 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01112)

Open in Phaseline: the race on HRAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Guangzhou JOYO PharmaJYP0015
Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS
KRAS, NRAS, HRASPhase 2Solid TumorDec 2026
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-10203
PI3Kα:RAS breaker
PIK3CA, KRAS, NRAS, HRASPhase 1Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung CancerAug 2027
Adlai Nortye BiopharmaAN9025
Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R
KRAS, NRAS, HRASPhase 1Solid Tumors (Phase 1)Jan 2028
Adlai Nortye BiopharmaAN4035
CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload
CEACAM5, KRAS, NRAS, HRASPhase 1Solid Tumor (Phase I)Dec 2028
Memorial Sloan Kettering Cancer CenterMSK-TCR5
T cell receptor (TCR) engineered to recognize RAS G12D mutations
KRAS, HRAS, NRASPhase 1Solid TumorJun 2030
Shanghai YingLi PharmaceuticalYL-17231
Pan-RAS inhibitor
KRAS, HRAS, NRASPhase 1Advanced Solid Tumors–

Conditions

Solid Tumor (2) Non-Small Cell Lung Cancer (1) Solid Tumor, Adult (1) Non-small Cell Lung Cancer (1) Solid Tumors (Phase 1) (1) Advanced Solid Tumors (1) Solid Tumor (Phase I) (1)

Modalities

small molecule (4), mixed (1), protein or peptide (1)

Companies

Adlai Nortye Biopharma (2) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Guangzhou JOYO Pharma (1) Shanghai YingLi Pharmaceutical (1) Memorial Sloan Kettering Cancer Center (1)

Related targets

KRAS (6) NRAS (6) PIK3CA (1) CEACAM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.